Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
QUILT-3.088: NANT Pancreatic Cancer Vaccine
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Drug: GemcitabineDrug: Aldoxorubicin HClDrug: Nab-paclitaxelBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNKDrug: AvelumabDrug: BevacizumabDrug: CapecitabineDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: Oxaliplatin
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03563144
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
- Conditions
- mCRCColorectal Cancer Metastatic
- Interventions
- Biological: Aldoxorubicin HydrochlorideBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNKDrug: AvelumabDrug: CapecitabineDrug: CetuximabDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: Nab-paclitaxelDrug: OxaliplatinDrug: RegorafenibProcedure: SBRT
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03563157
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
- Conditions
- Hepatocellular Carcinoma RecurrentHepatocellular Carcinoma Non-resectable
- Interventions
- Biological: ETBX-011Biological: GI-4000Biological: haNK for infusionBiological: avelumabDrug: CapecitabineDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: SorafenibProcedure: SBRTBiological: Aldoxorubicin hydrochlorideBiological: ETBX-051Biological: ETBX-061Biological: GI-6207Biological: GI-6301Drug: CetuximabBiological: N-803
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03563170
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 794
- Registration Number
- NCT03561740
- Locations
- 🇨🇳
Shusen Wang, Guangzhou, Guangdong, China
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
- Conditions
- NeoplasmsEndocrine Gland NeoplasmsEndocrine System DiseasesPancreatic NeoplasmsDigestive System NeoplasmAdenocarcinomaPancreatic DiseasesNeoplasm, GlandularNeoplasms PancreaticDigestive System Disease
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 48
- Registration Number
- NCT03535727
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 608
- Registration Number
- NCT03523585
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸The Methodist Hospital Research Institute, Houston, Texas, United States
🇧🇪Az Groeninge, Kortrijk, Belgium
Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Radiation: Hypofractionated ablative IMRT (HFA-IMRT)Drug: capecitabine
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT03523312
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer
- Conditions
- Anatomic Stage IIIC Breast Cancer AJCC v8Invasive Breast CarcinomaPrognostic Stage IIB Breast Cancer AJCC v8Breast Cancer FemaleAnatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03518242
- Locations
- 🇺🇬
Uganda Cancer Institute, Kampala, Uganda
🇺🇬New Mulago Hospital, Kampala, Uganda
Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers
- Conditions
- Gastrointestinal Cancer
- Interventions
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Tannaz Armaghany
- Target Recruit Count
- 6
- Registration Number
- NCT03515941
- Locations
- 🇺🇸
Baylor St. Lukes Medical Center, Houston, Texas, United States
🇺🇸Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas, United States
🇺🇸Harris Health System- Smith Clinic, Houston, Texas, United States
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
- Conditions
- Breast NeoplasmsBreast DiseasesCapecitabineHER2-positive Breast CancerHER2 Positive Breast CarcinomaHER2-positive Advanced Breast With Liver Metastases
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 301
- Registration Number
- NCT03500380
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.